Login to Your Account

Other News To Note

Friday, September 23, 2011
Vical Inc., of Bethesda, Md., reported animal data demonstrating synergistic improvement in efficacy using a combination of the company's Allovectin immunotherapy with an anti-CTLA-4 antibody in a melanoma animal model.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription